The Pim kinases: New targets for drug development

Current Drug Targets

Volumn 12, Issue 14, 2011, Pages 2059-2066

  Swords, Ronan ^a   Kelly, Kevin ^a   Carew, Jennifer ^a   Nawrocki, Stefan ^a   Mahalingam, Devalingam ^a   Sarantopoulos, John ^a   Bearss, David ^b   Giles, Francis ^a  

^a CTRC Institute for Drug Development   (United States)

^b SuperGen Inc   (United States)

Author keywords

Akt; Cell signalling; Drug development; Kinase; mTOR; PI3 kinase; PIM kinase

Indexed keywords

ABELSON KINASE; ADENOSINE TRIPHOSPHATE; CD135 ANTIGEN; I KAPPA B; IMIDAZOLE DERIVATIVE; JANUS KINASE 2; PROTEIN; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN KINASE PIM 3; PYRIDAZINE DERIVATIVE; RAPAMYCIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INACTIVATION; HUMAN; IN VITRO STUDY; LEUKEMIA; LYMPHOMA; MYELOMA; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; IMIDAZOLES; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1; PYRIDAZINES; SIGNAL TRANSDUCTION;

EID: 84855832562     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798829447     Document Type: Article

References (72)

1. Bachmann M, Moroy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 2005; 37(4): 726-30.
2. Meeker TC, Nagarajan L, ar-Rushdi A, Rovera G, Huebner K, Croce CM. Characterization of the human PIM-1 gene: a putative proto-oncogene coding for a tissue specific member of the protein kinase family. Oncogene Res 1987; 1(1): 87-101.
3. Mikkers H, Nawijn M, Allen J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004; 24(13): 6104-15.
4. Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 1999; 18(27): 4022-31.
5. Pircher TJ, Zhao S, Geiger JN, Joneja B, Wojchowski DM. Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death. Oncogene 2000; 19(32): 3684-92.
6. Lilly MB, Holder S, Zemskova M, Neidigh J. Use Of A Homology Model Of The PIM-1 Kinase To Identify Variant Flavonoids Having Selective Inhibitory Activity Against PIM-1. 2004; p. 2566-.
7. van Lohuizen M, Verbeek S, Krimpenfort P, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with cmyc and N-myc in murine leukemia virus-induced tumors. Cell 1989; 56(4): 673-82.
8. Akasaka H, Akasaka T, Kurata M, et al. Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. Cancer Res 2000; 60(9): 2335-41.
9. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci U S A 1989; 86(22): 8857-61.
10. Gourley ES, Liu X-H, Lamb JD, Vankayalapati H, Grand CL, Bearss DJ. Targeting Pim Kinases in Hematological Malignancies. 2007; p. 2655-.
11. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412(6849): 822-6.
12. Ragoussis J, Senger G, Mockridge I, et al. A testis-expressed Zn finger gene (ZNF76) in human 6p21.3 centromeric to the MHC is closely linked to the human homolog of the t-complex gene tcp-11. Genomics 1992; 14(3): 673-9.
13. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001; 412(6844): 341-6.
14. Hoover DS, Wingett DG, Zhang J, Reeves R, Magnuson NS. Pim-1 protein expression is regulated by its 5'-untranslated region and translation initiation factor elF-4E. Cell Growth Differ 1997; 8(12): 1371-80.
15. Mizuno K, Shirogane T, Shinohara A, Iwamatsu A, Hibi M, Hirano T. Regulation of Pim-1 by Hsp90. Biochem Biophys Res Commun 2001; 281(3): 663-9.
16. Losman J, Chen XP, Jiang H, et al. IL-4 signaling is regulated through the recruitment of phosphatases, kinases, and SOCS proteins to the receptor complex. Cold Spring Harb Symp Quant Biol 1999; 64: 405-16.
17. Xie Yn, Burcu M, Baer MR. PKC412 Directly Inhibits the Serine/Threonine Protein Kinase Pim-1 in Cell Lines and Acute Myeloid Leukemia Cells as a Novel Mechanism of Inhibition of Multidrug Resistance. ASH Annual Meeting Abstracts 2008; 112(11): 2655.
18. Gasser C, Grundler R, Brault L, et al. Dissecting Proto-Oncogenic PIM Serine/Threonine Kinases in FLT3-ITDInduced Leukemogenesis: PIM1 Regulates CXCL12/CXCR4-Mediated Homing and Migration. ASH Annual Meeting Abstracts 2008; 112(11): 3796.
19. Bullock AN, Russo S, Amos A, et al. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. PLoS One 2009; 4(10): e7112.
20. Baytel D, Shalom S, Madgar I, Weissenberg R, Don J. The human Pim-2 proto-oncogene and its testicular expression. Biochim Biophys Acta 1998; 1442(2-3): 274-85.
21. Fujii C, Nakamoto Y, Lu P, et al. Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Inter J Cancer 2005; 114(2): 209-18.
22. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 2006; 66(13): 6741-7.
23. Qian KC, Wang L, Hickey ER, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 2005; 280(7): 6130-7.
24. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115(10): 2618-24.
25. Wang Z, Bhattacharya N, Weaver M, et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2001; 2(3): 167-79.
26. Yip-Schneider MT, Horie M, Broxmeyer HE. Transcriptional induction of pim-1 protein kinase gene expression by interferon gamma and posttranscriptional effects on costimulation with steel factor. 1995; p. 3494-502.
27. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the proapoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004; 571(1-3): 43-9.
28. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91(2): 231-41.
29. Yan B, Zemskova M, Holder S, et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003; 278(46): 45358-67.
30. Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. 2005; p. 4477-83.
31. Hammerman PS, Fox CJ, Cinalli RM, et al. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation. Cancer Res 2004; 64(22): 8341-8.
32. Kane LP, Mollenauer MN, Xu Z, Turck CW, Weiss A. Aktdependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription. Mol Cell Biol 2002; 22(16): 5962-74.
33. Leverson JD, Koskinen PJ, Orrico FC, et al. Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol Cell 1998; 2(4): 417-25.
34. Rainio EM, Sandholm J, Koskinen PJ. Cutting edge: Transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J Immunol 2002; 168(4): 1524-7.
35. Koike N, Maita H, Taira T, Ariga H, Iguchi-Ariga SM. Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1). FEBS Lett 2000; 467(1): 17-21.
36. Maita H, Harada Y, Nagakubo D, et al. PAP-1, a novel target protein of phosphorylation by pim-1 kinase. Eur J Biochem 2000; 267(16): 5168-78.
37. Ishibashi Y, Maita H, Yano M, et al. Pim-1 translocates sorting nexin 6/TRAF4-associated factor 2 from cytoplasm to nucleus. FEBS Lett 2001; 506(1): 33-8.
38. Bhattacharya N, Wang Z, Davitt C, McKenzie IF, Xing PX, Magnuson NS. Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 2002; 111(2): 80-95.
39. Franke TF, Yang SI, Chan TO, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995; 81(5): 727-36.
40. Marte BM, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J. R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr Biol 1997; 7(1): 63-70.
41. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 16(20): 6151-61.
42. Giles F. A Pim kinase inhibitor. 2005; p. 4158-9.
43. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369(6483): 756-8.
44. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78(1): 35-43.
45. Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 2002; 13(7): 2276-88.
46. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22(5): 909-18.
47. Gao N, Zhang Z, Jiang BH, Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 2003; 310(4): 1124-32.
48. Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004; 101(9): 3130-5.
49. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004; 100(4): 657-66.
50. Jacobs MD, Black J, Futer O, et al. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 2005; 280(14): 13728-34.
51. Holder S, Zemskova M, Zhang C, et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 2007; 6(1): 163-72.
52. Cheney IW, Yan S, Appleby T, et al. Identification and structureactivity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2007; 17(6): 1679-83.
53. Bullock AN, Debreczeni JE, Fedorov OY, Nelson A, Marsden BD, Knapp S. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. J Med Chem 2005; 48(24): 7604-14.
54. Pogacic V, Bullock AN, Fedorov O, et al. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 2007; 67(14): 6916-24.
55. Lin Y, Song JH, Zhang Z, et al. Novel Small Molecule Pim Protein Kinase Inhibitors Induce Cell Cycle Arrest and Apoptosis in Human Leukemias: A Potential Therapeutic Approach. ASH Annual Meeting Abstracts 2008; 112(11): 1632.
56. Holder S, Lilly M, Brown ML. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg Med Chem 2007; 15(19): 6463-73.
57. Grey R, Pierce AC, Bemis GW, et al. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2009; 19(11): 3019-22.
58. Tong Y, Stewart KD, Thomas S, et al. Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling. Bioorg Med Chem Lett 2008; 18(19): 5206-8.
59. Qian K, Wang L, Cywin CL, et al. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J Med Chem 2009; 52(7): 1814-27.
60. Technology Up. the CLIMBTM, SuperGen Pharmaceuticals Inc., www.supergen.com.
61. Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47(7): 1739-49.
62. Jeremy G, G RJ, Albert CP. Compositions useful as Protein Kinase Inhibitors (Vertex) Patent WO 2004/058769, 2004.
63. Kumar A, Mandiyan V, Suzuki Y, et al. Crystal structures of protooncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 2005; 348(1): 183-93.
64. Ryan B, Prabha I, Kumar A, Mandiyan V, Milburn MV. Crystal Structure of PIM-1 Kinase. Patent WO 2004/024895, 2004.
65. Schrodinger LLC. New York (http: //www.schrodinger.com). QikProp Technical Notes; Schrodinger Press: Portland 2003.
66. Lipinski CA, Lambardo F, Dominy BW, Feeny PJ. Experimental and computational approches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 1997; 23: 3-25.
67. Bearss D, Liu X-H, Grand C, et al. Discovery and characterization of a small molecule inhibitor for Pim-1 kinase. American Society of Hematology National Meeting 2006; Abstract 414.
68. Bearss DJ, Liu X-H, Vankayalapati H, Xu Y. Preparation of imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives as protein kinase inhibitors. PCT Int Appl 2008; p. 107, Patent WO 2008058126.
69. Lamb J, Gourley E, Liu X-H, et al. A small kinase with activity in both hematological and solid tumor malignancies. AACR-NCIEOTRC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA 2007; Abstract 985.
70. Berk G. A Potent Small Molecule Pim Kinase Inhibitor with In vivo Oral Bioavailability and Activity in Cell Lines form Hematological Malignancies. European Hematology Association Abstract 2008.
71. Chen LS, Wierda WG, Redkar S, Bearss DJ, Gandhi V. Pim Kinase Inhibitor, SGI-1776, Induces Apoptosis in CLL Lymphocytes. ASH Annual Meeting Abstracts 2008; 112(11): 4199.
72. Brown VI, Sheen C, Hulitt J, et al. Inhibiting PIM-1 Is Effective in vitro and in vivo against ALL: A Novel Mechanistic and Potentially Clinically Relevant Druggable Target. ASH Annual Meeting Abstracts 2008; 112(11): 1922.